Dr. Aleksandar Shkondrov
Pharmacognosy, Medical University of Sofia, Sofia, Sofia-Grad, Bulgaria
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
13Years (2014-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications1 January 2016 in Pharmacognosy Reviews
Journal Article
IKIlina Nikolaeva Krasteva
Ilina Nikolaeva KrastevaVBViktor M Bratkov
Viktor M Bratkov
Aleksandar ShkondrovPZPetranka K Zdraveva
Petranka K Zdraveva
Flavonoids, the most common plant polyphenols are widely distributed in every species and possess a broad range of pharmacological activities. The genus Astragalus is the largest in the Fabaceae family with more than 2,500 species spread. They are known to contain different metabolites such as flavonoids, saponins, and polysaccharides. Plants from the genus have been used in the traditional medicine of many countries for centuries. This paper is focused on the large group of flavonoid compounds. Details on structure as well as information about the pharmacological properties of flavonoids, isolated from Astragalus species have been discussed. This review is based on publications until the first half of 2014 and includes also the results from our phytochemical investigations of the genus.
22 March 2014 in Phytochemistry Reviews
Journal Article
IIIliana Ionkova
Iliana Ionkova
Aleksandar ShkondrovIKIlina Nikolaeva Krasteva
Ilina Nikolaeva KrastevaTITodor Ionkov
Todor Ionkov
23 November 2018 in Natural Product Research
Journal Article
Aleksandar ShkondrovIKIlina Nikolaeva Krasteva
Ilina Nikolaeva Krasteva
Franz BucarOKOlaf Kunert
Olaf Kunert
MKMagdalena Kondeva-Burdina
Magdalena Kondeva-Burdina
IIIliana Ionkova
Iliana Ionkova
A new tetracyclic saponin, 17(R),20(R)-3β,6α,16β-trihydroxycycloartanyl-23-carboxylic acid 16-lactone 3-O-β-D-glucopyranoside (1) together with one known flavonoid, camelliaside A (2) were isolated from the aerial parts of Astragalus glycyphyllos L. Their structures were determined by chemical, HRESIMS and NMR methods. On 6-hydroxydopamine in vitro model on isolated rat brain synaptosomes, compounds 1–2 had statistically significant neuroprotective activity similar to that of Silibinin, tested at 100 μM. Saponin 1 possessed the most prominent neuroprotective and antioxidant effects in this in vitro model. On human recombinant monoamine oxidase type B enzyme compound 1 displayed strong inhibiting activity, compared to Selegiline (1 μM). It could be concluded that the new epoxycycloartane saponin 1 could be a promising leading structure in respect of neurodegenerative diseases.
1 January 2018 in Food and Chemical Toxicology
Journal Article
MKMagdalena Kondeva-Burdina
Magdalena Kondeva-BurdinaAleksandar Shkondrov
Rumyana SimeonovaVVVessela Vitcheva
Vessela Vitcheva
IKIlina Nikolaeva Krasteva
Ilina Nikolaeva KrastevaIIIliana Ionkova
Iliana Ionkova
Journal Article
ISIvan Stambolov
Ivan StambolovAleksandar ShkondrovOKOlaf Kunert
Olaf KunertFranz BucarMKMagdalena Kondeva-Burdina
Magdalena Kondeva-BurdinaIKIlina Nikolaeva Krasteva
Ilina Nikolaeva KrastevaAstragalus glycyphyllos (Fabaceae) is used in the traditional medicine of many countries against hepatic and cardiac disorders. The plant contains mainly flavonoids and saponins. From a defatted methanol extract from its overground parts, a new triterpenoid saponin, 3-O-[α-L-rhamnopyranosyl-(1→2)]-β-D-xylopyranosyl]-24-O-α-L-arabinopyranosyl-3β,6α,16β,24(R),25-pentahydroxy-20R-cycloartane, together with the rare saponin astrachrysoside A, were isolated using various chromatography methods. The compounds were identified via extensive high resolution electrospray ionisation mass spectrometry (HRESIMS) and NMR analyses. Both saponins were examined for their possible antioxidant and neuroprotective activity in three different in vitro models. Rat brain synaptosomes, mitochondria, and microsomes were isolated via centrifugation using Percoll gradient. They were treated with the compounds in three different concentrations alone, and in combination with 6-hydroxydopamine or tert-butyl hydroperoxide as toxic agents. It was found that the compounds had statistically significant dose-dependent in vitro protective activity on the sub-cellular fractions. The compounds exhibited a weak inhibitory effect on the enzyme activity of human recombinant monoamine oxidase type B (hMAO-B), compared to selegiline.
26 November 2020 in Pharmacia
Journal Article
MVMaria Voynova
Maria Voynova
Aleksandar ShkondrovMKMagdalena Kondeva-Burdina
Magdalena Kondeva-Burdina
IKIlina Krasteva
Ilina Krasteva
Amanita muscaria, commonly known as fly agaric, is a basidiomycete. Its main psychoactive constituents are ibotenic acid and muscimol, both involved in ‘pantherina-muscaria’ poisoning syndrome. The rising pharmacological and toxicological interest based on lots of contradictive opinions concerning the use of Amanita muscaria extracts’ neuroprotective role against some neurodegenerative diseases such as Parkinson’s and Alzheimer’s, its potent role in the treatment of cerebral ischaemia and other socially significant health conditions gave the basis for this review. Facts about Amanita muscaria’s morphology, chemical content, toxicological and pharmacological characteristics and usage from ancient times to present-day’s opportunities in modern medicine are presented.
About Me
Dr. Aleksandar Shkondrov graduated from the Faculty of Pharmacy at the Medical University of Sofia in 2012. Since 2016, he has been an assistant, and since 2018, he has been a chief assistant professor at the Department of Pharmacognosy. He defended his doctoral dissertation in pharmacognosy and phytochemistry on “Phytochemical study of species of the genus Astragalus L.”. He has a specialty in Medicinal Plants and Phytopharmaceuticals, acquired through the Post Graduate Specialisation at
Medical University of Sofia. He participates in the training on “Pharmacognosy” for pharmacy students. His research work and contributions mainly focus on areas of pharmaceutical science and practice (phytochemistry, analysis of biologically active substances of natural origin, and pharmacognosy). He is an
expert in phytochemistry and pharmacognosy. He is a participant in 18 research projects funded by the Council of Medical Science at Medical University and the National Research Fund at the Bulgarian Ministry of Education and Science. He is a reviewer of many scientific journals reviewed and indexed by Elsevier’s Scopus and Clavirate’s Web of Science. Also, he is a member of several professional organizations and associations, including the Bulgarian Pharmaceutical Union, Bulgarian Scientific Society of Pharmacy, Bulgarian Phytochemical Association, Bulgarian Society of Toxicology, and more.